| Name | PSMA-ALB-56 |
|---|
| Description | PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder[1]. |
|---|---|
| Related Catalog | |
| Target |
Traditional Cytotoxic Agents |
| In Vivo | PSMA-ALB-56 accumulates much faster in tumor tissues and is more efficiently cleared from the blood and background tissues, which results in excellent tumor-to-background contrast already 4 hours after injection. PSMA-ALB-56 increases median survival in mice[1]. |
| References |
| Molecular Formula | C66H95N11O18 |
|---|---|
| Molecular Weight | 1330.52 |